Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis

Abstract

Design, study conduct, and financial support for this study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract. All authors contributed to the development of the publication and maintained control over the final content. Rubin has received consulting fees or research support from AbbVie, Amgen, Emmi, Genentech, Ironwood, Janssen, Pfizer, Prometheus, Shire, and Takeda. Skup and Mittal are employees and stockholders of AbbVie. Chao was an employee of AbbVie at the time of the study and may hold AbbVie stock. Johnson and Davis are employees of Medicus Economics, which received payment from AbbVie to participate in this research. Study concept and design were contributed by Rubin, Mittal, Chao, and Skup, along with Davis and Johnson. Davis and Johnson took the lead in data collection, with assistance from the other authors, and data interpretation was performed by Rubin, Mittal, Chao, and Skup, with assistance from Davis and Johnson. All authors contributed to the writing and revision of the manuscript. The abstract for this study was published as Rubin DT, Skup M, Davis M, Johnson S, Chao J. Impact of AbbVie's patient support program on resource costs in Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis. J Manag Care Spec Pharm. 2015;21(Suppl 4a):S74-75 (poster presentation at Academy of Managed Care, 27th Annual Meeting and Expo; April 7-10, 2015; San Diego, CA) and as abstract 2339 in Arthritis Rheumatol. 2015;67(Suppl 10; poster presentation at American College of Rheumatology 2015 ACR/AHRP Annual Meeting; November 7-11, 2015; San Francisco, CA).

A randomized controlled clinical trial to assess the impact of motivational phone calls on therapeutic adherence in patients suffering from psoriasis

“…However, a trend toward more stringent adherence to topical therapies and lower reported adverse effects was noted in the interventional group. MPCs may thus become a relevant component of integrated protocols that utilize other potentially beneficial adherence-enhancing strategies (Alinia et al, 2017;Balato, Megna, Di Costanzo, Balato, & Ayala, 2013;Feldman et al, 2017;Hawkins, Barilla, & Feldman, 2017;Hong, Papp, Lophaven, Skallerup, & Philipp, 2017;Reich, Mrowietz, Karakasili, & Zschocke, 2014;Reich et al, 2017;Rubin et al, 2017), such as textmessage reminders. MPC = motivational phone call; visit 1 = first appointment, at time of enrollment; visit 2 = second appointment, at time of conclusion (6 AE 1 months after enrollment).…”

Impact of the Adalimumab Patient Support Program on Clinical Outcomes in Ankylosing Spondylitis: Results from the COMPANION Study

“…Participation in the PSP has been associated with significantly reduced total cost, all-cause medical cost, and disease-related medical cost in patients with Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and AS treated with ADA [11]. However, a formal economic evaluation was not within the scope of the current study, and real-world studies in the future can focus on examining the economic impact of PSP strategies, specifically in patients with AS treated with ADA.…”

“…Both short-term and long-term clinical studies have demonstrated the efficacy and safety of TNF antagonists in patients with AS [10]. However, poor persistence with and non-adherence to treatment with biologics can undermine the effectiveness of these medications [11,12]. Considering the high rates ([ 40%) of non-adherence observed with chronic TNF antagonist treatment [12], it is necessary to explore approaches to improve patient adherence.…”

Ab1236 improving Clinical Outcome and Reducing Cost for Patients With Rheumatic Diseases via Online Interaction With Rheumatologists Based on Smart System of Disease Management (Ssdm) Mobile Tool

“…Background: The diagnosis of rheumatoid arthritis (RA) using EULAR criteria through conventional assessments remains controversial, especially for those with seronegative results, many of patients without other diagnostic aids as imaging, could be wrong diagnosed followed by expensive treatments (1)(2)(3). Objectives: To evidence through real-world data how the use of imaging within a screening process of diagnosis of RA can saving future costs for unnecessary treatments in patients with misdiagnosis of RA.…”